Dalfampridine
Tier C — Watch / tradeDalfampridine
Targets：Potassium channel, VGKCs
Brand：Fampyra, Neurelan, Amaya, Ampyra
Indications (approved)：Multiple sclerosis
Regional status
Factories producing this API3
Factories registered as producing this API in our sourcing network (RFQ records + product master), sorted by RFQ activity; the snapshot carries no cost or customer data.
3 producing factories on file — sign in to view the named list (factory details are not shown to guests).
Sign in to view factories →Synthetic routes & intermediates4 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
Frequently asked questions
What are the approved indications of Dalfampridine?
Approved indications include: Multiple sclerosis.
When does the Dalfampridine patent expire?
No public expiry year is available for Dalfampridine yet; this page updates once verified.
How many synthesis routes are recorded for Dalfampridine?
4 synthesis routes are recorded; the shortest is 1 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Dalfampridine intermediates?
All intermediates in Dalfampridine routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Dalfampridine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29